3D interactions between the ligand and the protein_DNA complex in the first (C1) and second (C2) clusters. by Ahmed A. Gaber (13302308)

Subjects:

Binding of amsacrine with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

The center of mass distances between the protein-DNA complex and the ligand (Blue line), and the protein and DNA (red line). by Ahmed A. Gaber (13302308)

Subjects:

Fig 12 - by Ahmed A. Gaber (13302308)

Subjects:

The number of clusters, number of interactions, and their types between the ligand and protein_DNA complex. by Ahmed A. Gaber (13302308)

Subjects:

Binding of compound 17 with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

Fig 4 - by Ahmed A. Gaber (13302308)

Subjects:

Some reported DNA intercalators and their basic pharmacophoric features. by Ahmed A. Gaber (13302308)

Subjects:

The contributions from the different energy components of MM-GBSA. by Ahmed A. Gaber (13302308)

Subjects:

Binding of compound 19 with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

The immunoblotting of BAX and Bcl-2 (Normalized to β-actin). by Ahmed A. Gaber (13302308)

Subjects:

Binding of compound 12b with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

The antiproliferative activities of the tested compounds toward HepG2, and HCT‐116 cell lines, Topo II activity, and DNA‐intercalating affinity. by Ahmed A. Gaber (13302308)

Subjects:

The docking binding free energies (ΔG) of the synthesized compounds with DNA-topoisomerase II complex. by Ahmed A. Gaber (13302308)

Subjects:

The rationale of molecular design of new DNA-intercalators. by Ahmed A. Gaber (13302308)

Subjects:

Image_1_Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets’ Disease-Associated Uveitis: A Systematic Review and Meta-Analysis.jpeg by Yunwei Hu (9021272)

“…The number of patients in each study ranged from 11 to 163 and the mean follow-up time from 0.9 to 6.44 years. During the follow-up, the pooled inflammation remission rate was 68% with a 95% confidence interval (CI) of 0.59–0.79, VA improvement rate was 60% (95% CI 0.47–0.77), CMT decrease was 112.70 μm (95% CI 72.8–153.0 μm). …”

Table_1_Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets’ Disease-Associated Uveitis: A Systematic Review and Meta-Analysis.docx by Yunwei Hu (9021272)

“…The number of patients in each study ranged from 11 to 163 and the mean follow-up time from 0.9 to 6.44 years. During the follow-up, the pooled inflammation remission rate was 68% with a 95% confidence interval (CI) of 0.59–0.79, VA improvement rate was 60% (95% CI 0.47–0.77), CMT decrease was 112.70 μm (95% CI 72.8–153.0 μm). …”

Population entropy in APP/PS1 mice is decreased in dCA1, but increased in vCA1. by Udaysankar Chockanathan (18510288)

<i>Salmonella</i> infection but not challenge by microspheres decreases surface-exposed sialic acids and reduces the negativity of BMDMs. by Yaohui Sun (400875)

Pairwise correlations in APP/PS1 mice are decreased in dCA1, but increased in vCA1. by Udaysankar Chockanathan (18510288)